Boundless Bio Overview
- Year Founded
-
2018
- Status
-
Public
- Employees
-
28
- Stock Symbol
-
BOLD
- Investments
-
1
- Share Price
-
$2.47
- (As of Thursday Closing)
Boundless Bio General Information
Description
Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.
Contact Information
Website
www.boundlessbio.comCorporate Office
- 10955 Alexandria Way
- Suite 100
- San Diego, CA 92121
- United States
Corporate Office
- 10955 Alexandria Way
- Suite 100
- San Diego, CA 92121
- United States
Boundless Bio Stock Performance
As of 12-Nov-2026, Boundless Bio’s stock price is $2.47. Its current market cap is $58.1M with 23.6M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.47 | $2.46 | $0.96 - $3.16 | $58.1M | 23.6M | 132K | -$2.47 |
Boundless Bio Financials Summary
As of 30-Sep-2026, Boundless Bio has a trailing 12-month revenue of null.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | (15,529) | (40,948) | (102,344) | |
| Revenue | 0 | 0 | 0 | 0 |
| EBITDA | (56,851) | (62,254) | (72,155) | (53,759) |
| Net Income | (55,497) | (58,197) | (65,363) | (49,434) |
| Total Assets | 63,594 | 157,059 | 206,409 | 129,894 |
| Total Debt | 0 | 49,035 | 47,632 | 2,195 |
Boundless Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Boundless Bio Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Boundless Bio Comparisons
Industry
Financing
Details
Boundless Bio Competitors (34)
One of Boundless Bio’s 34 competitors is Adaptimmune Therapeutics, a Formerly VC-backed company based in Abingdon, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Intellia Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Genelux | Formerly VC-backed | Westlake Village, CA | ||||
| Senti Biosciences Holdings | Formerly VC-backed | South San Francisco, CA | ||||
| Adimab | Venture Capital-Backed | Lebanon, NH |
Boundless Bio Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Boundless Bio Patents
Boundless Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026178314-A1 | Kif22 degraders and uses thereof | Pending | 21-Feb-2025 | ||
| WO-2026178315-A1 | Kif22 inhibitors and uses thereof | Pending | 21-Feb-2025 | ||
| EP-4770642-A2 | Ribonucleotide reductase (rnr) compositions and methods of use | Pending | 01-Sep-2023 | ||
| WO-2025049814-A2 | Ribonucleotide reductase (rnr) compositions and methods of use | Inactive | 01-Sep-2023 | ||
| WO-2025049814-A3 | Ribonucleotide reductase (rnr) compositions and methods of use | Inactive | 01-Sep-2023 | A61P35/00 |
Boundless Bio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Boundless Bio Acquisitions (1)
Boundless Bio’s most recent deal was a Reverse Merger with Serapha Bio. The deal was made on 22-Jun-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Serapha Bio | 22-Jun-2026 | Reverse Merger | Discovery Tools (Healthcare) |
Boundless Bio ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
38.02 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,585
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Boundless Bio FAQs
-
When was Boundless Bio founded?
Boundless Bio was founded in 2018.
-
Where is Boundless Bio headquartered?
Boundless Bio is headquartered in San Diego, CA.
-
What is the size of Boundless Bio?
Boundless Bio has 28 total employees.
-
What industry is Boundless Bio in?
Boundless Bio’s primary industry is Drug Discovery.
-
Is Boundless Bio a private or public company?
Boundless Bio is a Public company.
-
What is Boundless Bio’s stock symbol?
The ticker symbol for Boundless Bio is BOLD.
-
What is the current stock price of Boundless Bio?
As of 12-Nov-2026 the stock price of Boundless Bio is $2.47.
-
What is the current market cap of Boundless Bio?
The current market capitalization of Boundless Bio is $58.1M.
-
Who are Boundless Bio’s competitors?
Adaptimmune Therapeutics, Intellia Therapeutics, Genelux, Senti Biosciences Holdings, and Adimab are some of the 34 competitors of Boundless Bio.
-
What is Boundless Bio’s annual earnings per share (EPS)?
Boundless Bio’s EPS for 12 months was -$2.47.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
